NeoTract touts 4-year UroLift data

NeoTract today released the results from 2 randomized studies of its UroLift system designed to treat benign prostatic hyperplasia, touting “excellent” durability after 4 years. The data was presented at the American Urological Association’s 2016 annual meeting in San Diego this week. “The clinical data presented at this year’s AUA conference show that treatment with the UroLift System offered men suffering from BPH a well-tolerated minimally invasive experience that provided uniquely rapid relief and a durable, sustained effect. We are proud to offer this safe and effective treatment option that can allow men to stop taking BPH medications and be treated with a simple procedure that does not carry the risk of sexual side effects common with other treatment options,” CEO Dave Amerson said in a press release. Included in the presentations were 4-year follow up data from the pivotal, randomized Lift IDE study and 2-year data from the BPH-6 study which compared the UroLift system to transurethral resection of the prostate. Data from the 206-patient mult-center Lift IDE study indicated rapid reduction of symptoms with low mobidity and preserved sexual function, 62% improved International Prostate Symptom and Qmax scores as well as a 52% increase in quality of life scores over 4-years, the company said. “While prior data have shown that this treatment option offers rapid relief with low morbidity, the four-year L.I.F.T. study data demonstrate...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Urology NeoTract Source Type: news